GHO Capital Invests in RoslinCT

GI Partners Completes Acquisition of Charles River’s CDMO and Cell Solutions Businesses, Forms Rose BioSolutions

May 8, 2026

Healthcare Services

GI Partners completed its acquisition of the Contract Development and Manufacturing Organization (CDMO) and Cell Solutions businesses from Charles River Laboratories, creating an independent advanced therapy manufacturing company, Rose BioSolutions. Rose BioSolutions will provide end-to-end cell and gene therapy development and manufacturing, covering plasmid DNA, viral vectors, cell therapy production, and cellular starting materials.

Ampersand Capital Partners Leads $18.5M Growth Investment in Genezen

November 2, 2023

Biotechnology

Genezen closed an $18.5 million follow-on growth equity financing led by Ampersand Capital Partners to accelerate expansion of its viral vector development and GMP manufacturing capabilities. The capital will support build-out and technology investments at Genezen's facilities (including the Fishers, Indiana GMP viral vector site) to scale retroviral, lentiviral and AAV vector production and support additional customer programs.

GHO Capital and Partners Group Invest in Sterling Pharma Solutions

May 25, 2023

Pharmaceuticals

GHO Capital (majority owner) and Partners Group have completed an investment into GHO portfolio company Sterling Pharma Solutions, with Partners Group acquiring a significant minority stake. The transaction is supported by a consortium led by funds managed by AlpInvest Partners and Pantheon and will fund Sterling's expansion of production capacity, capability build-out and further strategic acquisitions across the UK, Europe and the US.

Ampersand Capital Partners Invests in Genezen Laboratories

January 5, 2021

Biotechnology

Ampersand Capital Partners has made a majority growth-equity investment in Genezen Laboratories, a cell and gene therapy CDMO, to fund completion of a 25,000 sq. ft. cGMP lentiviral vector production facility and expand process development and analytical testing capabilities. The capital will support Genezen's capability expansion across upstream/downstream processing, analytical testing, and cGMP vector production to serve early‑phase and growth-stage cell and gene therapy developers.

WindRose Health Investors Recapitalizes Lykan Bioscience Holdings

June 4, 2019

Biotechnology

WindRose Health Investors completed an equity recapitalization of Lykan Bioscience Holdings, LLC, a Hopkinton, Massachusetts-based contract manufacturing services organization focused on cell and gene therapy production and logistics. The investment provides capital to support growth and the build-out of a 60,000+ square foot cGMP facility to expand manufacturing capacity; terms were not disclosed.

GHO Capital Acquires Majority Stake in Sterling Pharma Solutions

February 28, 2019

Pharmaceuticals

GHO Capital has acquired a majority stake in Sterling Pharma Solutions alongside management. The investment will support Sterling's international expansion and accelerate growth of its specialist API development and GMP manufacturing capabilities from its UK base in Newcastle upon Tyne.